GeoVax Labs, Inc.

GOVXSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 832489

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Research and Development Expense	$20.7M	$9.1M	$15.6M	$2.4M	$1.9M
Operating Expenses	$26.7M	$14.1M	$19.1M	$4.6M	$3.5M
Operating Income (Loss)	-$26.7M	-$14.0M	-$18.7M	-$2.8M	-$2.4M
Interest Expense	—	—	$1.3K	$143.5K	$4.5K
Nonoperating Income (Expense)	$776.2K	—	$175.5K	-$141.3K	$1.9K
Income Tax Expense (Benefit)	—	—	—	$0.00	$0.00
Net Income (Loss) Attributable to Parent	-$26.0M	-$14.0M	-$18.6M	-$3.0M	-$2.4M
Earnings Per Share, Basic	-$14.29	-$12.39	-$3.04	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$9.3M	$31.3M	$11.8M	$10.4M	$468.9K
Assets, Current	$7.9M	$28.9M	$11.6M	$10.2M	$447.3K
Cash and Cash Equivalents, at Carrying Value	$6.5M	$27.6M	$11.4M	$9.9M	$283.3K
Accounts Receivable, after Allowance for Credit Loss, Current	$0.00	—	—	—	—
Liabilities	—	—	$7.4M	$825.0K	$2.0M
Liabilities, Current	$3.5M	$4.7M	$5.4M	$810.3K	$2.0M
Accounts Payable, Current	$2.8M	$1.7M	$2.1M	$267.7K

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$25.2M	-$19.0M	-$11.2M	-$2.8M	-$1.4M
Net Cash Provided by (Used in) Investing Activities	-$48.9K	-$134.3K	-$47.7K	-$156.8K	-$7.6K
Net Cash Provided by (Used in) Financing Activities	$4.1M	$35.4M	$12.8M	$12.5M	$1.4M
Payments to Acquire Property, Plant, and Equipment	$48.9K	$134.3K	$47.7K	$156.8K	$7.6K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)